BIOLOGY IS COMPLEX
Precision medicine has yet to deliver on its full potential. That’s where Auransa is making a difference.
WE ARE COMMITTED TO BUILDING A NEW KIND OF PHARMACEUTICAL COMPANY
One that uses AI and genomics to develop novel therapeutics for disease subtypes. One that can tackle the underlying heterogeneity of diseases. One that makes drug discovery and development a lot smarter.
UNPRECEDENTED PREDICTIVE POWER
to identify disease subtypes and create more biologically and clinically relevant treatments.
Auransa’s powerful computational platform delivers unprecedented predictive power to identify disease subtypes and create more biologically and clinically relevant treatments. We have identified patient subtypes across more than 30 diseases, and our most advanced therapeutic programs are progressing through preclinical development towards IND. SMarTR Engine
ADVANCED LIQUID BIOPSY TECHNOLOGY
sends drug candidates into clinical trials knowing which patients should be responsive to treatment.
CTSeek Liquid Biopsy
Our advanced liquid biopsy technology works in concert with our therapeutics. Auransa’s CTSeek platform is based on a novel approach that describes circulating tumor cells in a non-invasive, information-rich manner. CTSeek
AURANSA UNDERSTANDS THAT DRUG DEVELOPMENT REQUIRES MORE THAN A PREDICTIVE ENGINE
That’s why we set out from day one to assemble a team that encompasses wet bench and dry bench expertise. Together, we’re committed to finding solutions that ultimately save lives and improve human health.
AURANSA IS BACKED BY LEADING VENTURE CAPITAL INVESTORS AND SUCCESSFUL BIOTECH VETERANS